An observational study in Cardiac Arrest, Neurologic Symptoms and Intensive Care Neurological Disorder, sponsored by Nantes University Hospital. Recruiting at 4 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Nantes University Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 106 studies in Heart Arrest with a site in France — 32 open to participants now, 33 under way, 3 of them phase 3. Heart Arrest · France.
Among the 106 studies in Heart Arrest with a site in France, this one is the 7th largest by planned enrollment of the 47 observational ones that give a count, is one of 10 that started in 2025, is one of 47 observational ones, reaches primary completion later than 13 of the 32 other live ones, and was the 86th registered.
927 studies on the registry are indexed under Heart Arrest; 227 are open to participants now.
Browse Heart Arrest studies →32 of the 106 studies in Heart Arrest with a site in France are open now. Recruiting first, the newest first:
Nantes University Hospital · Sites in France, Belgium, Guadeloupe
Ages 18+
University Hospital, Toulouse · Sites in France
Ages 18+
Nantes University Hospital · Sites in France
Ages 18+
University Hospital, Toulouse · Sites in France
Ages 18+ · Healthy volunteers
Versailles Hospital · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 157 Heart Arrest studies recruiting now, 109 (69%) set no upper age limit and 28 (18%) stop at 75 or younger; 30 take children under 18; 18 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
106 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 10 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 608 is above the median of 200 across 376 observational studies indexed under Heart Arrest.
Median enrollment 106 across the 59 interventional studies, 150 across the 47 observational. Of the 62 that completed or were terminated, 3 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 106 have an industry lead sponsor. The 10 most frequent:
Nantes University Hospital is the lead sponsor of 839 studies on the registry; 189 are open to participants now.
Nantes University Hospital has 5 studies filed under Heart Arrest — fewer than ten, so there is no comparison to draw.
8 of the studies in Heart Arrest with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06835491Phase 3Versailles HospitalProphylactic Anti-aRrhythmic Therapy With Amiodarone in Critically Ill Patients Admitted for an Out-of-hospital Cardiac Arrest With Initial Shockable Rhythm | 2027-01-15 |
| NCT03594318Versailles HospitalVersailles Hospital Cardiac Arrest Registry | 2026-12 |
| NCT06387225Nantes University HospitalEarly and Objective Assessment of Neurological Prognosis in Cardiac Arrest Patients | 2027-05-31 |
| NCT05961488CHU de ReimsPerformance of Coronary CT Angiography to Rule Out Coronary Artery Disease After Out-of-hospital Cardiac Arrest | 2027-06 |
| NCT06780722Nantes University HospitalStudy of the Occurrence of Cardiocirculatory Arrest as a Function of the Level of Hypoxemia During a Maastricht 3 Procedure | 2027-06-06 |
Add all 8 to your calendar (.ics) → With an account.
Among the 106 studies in Heart Arrest with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Cerebral lesions are responsible for two thirds of deaths in patients admitted to intensive care following cardiac arrest. Patients with neurological lesions should be the priority target for neuroprotective interventions, which are the cornerstone of post-cardiac arrest care (allowing a reduction in the burden of care for patients without this type of lesion). Furthermore, these interventions must be based on a precise assessment of the severity of these brain lesions: carrying out neuro-protective interventions in patients without brain lesions exposes these patients to unnecessary treatment potentially associated with adverse effects without any possible benefit. However, the early assessment of neurological prognosis, particularly on admission to intensive care, is an area where there is little research and where it is not possible to obtain a precise and reproducible assessment. Several tools can be used to assess this prognosis at an early stage: anamnesis and characteristics of the cardiac arrest and the patient's comorbidities, imaging, electrophysiology and biomarkers.
To assess the predictive value of early biomarker testing in patients resuscitated after cardiac arrest, whatever the cause, the investigators plan to conduct a prospective observational multicentre trial.
It is important to bear in mind that the aim of this study is not to assess the long-term prognosis of patients suffering cardiac arrest in order to take measures to limit or discontinue active therapies, but simply to provide a reliable tool, simple and quick to use, in order to be able to identify a sub-population of patients who should be the subject of preferential neuro-protection measures, and conversely to simplify management (moderate temperature control, early cessation of sedation, early extubation) for patients with no neurological lesions.
Patients will be included on admission to intensive care.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Dosage of biomarker UCHL-1 (Ubiquitin carboxy-terminal hydrolase L1) at the time of admission to intensive care
Determine an assay threshold value admission to the intensive care unit to predict membership of a homogeneous group with favorable neurological outcome at D90
Time frame: at ICU admission
Dosage of biomarker GFAP (Glial fibrillary acidic protein) at the time of admission to intensive care
Determine an assay threshold value admission to the intensive care unit to predict membership of a homogeneous group with favorable neurological outcome at D90
Time frame: at ICU admission
Neurological outcome at D90 assessed by modified Rankin scale (mRS)
Determine an assay threshold value admission to the intensive care unit to predict membership of a homogeneous group with favorable neurological outcome at D90
Time frame: 90 days after patient enrolment in the study
Dosage of biomarkers UCHL-1 ((Ubiquitin carboxy-terminal hydrolase L1) at the time of admission to intensive care
Determine prognostic value (positive and negative predictive value (PPV/NPV), positive and negative likelihood ratio (LR+/LR-) of each biomarker separately according to the threshold on admission. Determine the value of combining the two biomarkers at admission.
Time frame: at ICU admission
Dosage of biomarkers GFAP (Glial fibrillary acidic protein) at the time of admission to intensive care
Determine prognostic value (positive and negative predictive value (PPV/NPV), positive and negative likelihood ratio (LR+/LR-) of each biomarker separately according to the threshold on admission. Determine the value of combining the two biomarkers at admission.
Time frame: at ICU admission
Dosage of biomarkers UCHL-1 (Ubiquitin carboxy-terminal hydrolase L1) at 4 hours for recovery of effective cardiac activity (RACS)
Determine a threshold value at H4 for recovery of effective cardiac activity (RACS) to predict membership of a homogeneous group with a favorable neurological outcome at D90. Determine interest of combining the two biomarkers at H4 of the RACS.
Time frame: at 4 hours for recovery of effective cardiac activity (RACS)
Dosage of biomarkers GFAP( Glial fibrillary acidic protein) at 4 hours for recovery of effective cardiac activity (RACS)
Determine a threshold value at H4 for recovery of effective cardiac activity (RACS) to predict membership of a homogeneous group with a favorable neurological outcome at D90. Determine interest of combining the two biomarkers at H4 of the RACS.
Time frame: at 4 hours for recovery of effective cardiac activity (RACS)
Neurological outcome at D90 assessed by modified Rankin scale (mRS) ranging from 0 to 6
Determine a threshold value at H4 for recovery of effective cardiac activity (RACS) to predict membership of a homogeneous group with a favorable neurological outcome at D90. A score of 0 to 3 is considered a favorable neurological outcome.
Time frame: 90 days after patient enrolment in the study
Started Feb 2025 (actual). Primary completion is estimated for May 2027, 27 months after the start.
Of 169 non-industry observational studies under Heart Arrest, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 96. This study's planned 27 months is below that.
Counting every sponsor, half of 176 studies reached it within 41 months; a quarter within 18 and three quarters within 90.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.